C-CAR011 Treatment in Subjects With ALL After HSCT

Inclusion Criteria: * Age 15-65 years old, male or female. * Volunteered to participate in this study and signed informed consent. * Meet the two populations above. * Histologically diagnosed as CD19+B-ALL. * 100% T lymphocytes of donor. * Treatment without chemotherapy and antibody therapy within 2 weeks prior to C-CAR011 therapy. * Left ventricular ejection fraction (LVEF) ≧ 50%, no evidence of pericardial effusion and clinically significant arrhythmias. * Baseline oxygen saturation ≧ 92% on room air and with normal pulmonary function, no evidence of active lung infection. * Expected survival ≧ 3 months. * Eastern cooperative oncology group (ECOG) performance status of 0 or 1. Exclusion Criteria: * History of allergy to cellular products. * Any kind of these laboratory testing: serum total bilirubin≧2.0mg/dl, serum albumin\<35g/L, ALT, AST≧3×ULN, serum creatinine≧2.0mg/ dl,platelets\<20×109/L. * The subjects had active aGVHD with II-IV degrees (Glucksberg degrees) or active moderate to severe cGVHD. * Severe uncontrolled infection (mycotic, bacterial, virus and so on). * Any central nervous system leukemia(CNS2, CNS3) , with insensitive to intrathecal injection of or radiotherapy of head/spine; but effectively controlled cases will be eligible. * The subjects were treated CART cells or DLI after HSCT. * Bone marrow failure syndrome（BMF） after allogeneic hematopoietic stem cell transplantation. * Any genetically modified T cell therapy. * History of heavy drinking, drug taking or mental disease. * Participated in any other clinical trial within one month prior to enrollment. * Women who are pregnant or lactating or have breeding intent in 6 months. * The investigators believe that any increase in the risk of the subject or interference with the results of the trial.